Ludwig E H, Hopkins P N, Allen A, Wu L L, Williams R R, Anderson J L, Ward R H, Lalouel J M, Innerarity T L
Department of Human Genetics and Howard Hughes Medical Institute, University of Utah, Salt Lake City 84112, USA.
J Lipid Res. 1997 Jul;38(7):1361-73.
To search for unique mutations in the apolipoprotein B (apoB) gene that disrupt the binding of LDL to its receptor and cause hypercholesterolemia, we examined more than 800 patients with high LDL cholesterol levels and/or coronary artery disease (CAD). Analysis of patient DNA by single-strand conformation polymorphism and allele-specific oligonucleotide hybridization of the sequence surrounding the putative receptor- binding domain of apoB (amino acid positions 2965 to 3534) revealed seven variations. LDL from heterozygotes with either Arg 3500 Gln or Arg 3531 Cys bound defectively with the LDL receptor in competitive binding assays. The Arg 3500 Gln substitution was statistically more prevalent in patients with hypercholesterolemia (P = 0.0003). Total cholesterol and LDL-cholesterol were significantly higher (P< 0.0004) in 34 apoB 3500 Gln carriers than in the controls. The allele encoding the Arg 3531 Cys substitution was more prevalent (0.8%) in the CAD group (P = 0.05) than in the controls. A Ser 3252 Gly variant was statistically more prevalent in the hypercholesterolemic group (P = 0.03), but LDL with this mutation had normal LDL receptor-binding activity. The other four variants identified (Leu 3350 Leu, Gln 3405 Glu, Val 3396 Met, and Ser 3455 Arg) were not associated with defective LDL-receptor binding, hypercholesterolemia, or CAD, nor were the apoB mutations associated with elevated lipid levels in family members. The surprising result that only two mutations of apoB in the receptor-binding domain (Arg 3500 Gln and Arg 3531 Cys) were associated with defective LDL binding, hypercholesterolemia, or CAD is in stark contrast with familial hypercholesterolemia, where nearly 150 mutations of the LDL receptor have been described that disrupt its function. This study strongly suggests that a limited number of mutations of apoB markedly influence LDL binding to its receptor.
为了寻找载脂蛋白B(apoB)基因中能够破坏低密度脂蛋白(LDL)与其受体结合并导致高胆固醇血症的独特突变,我们检查了800多名低密度脂蛋白胆固醇水平高和/或患有冠状动脉疾病(CAD)的患者。通过单链构象多态性分析患者DNA,并对apoB假定受体结合域周围序列(氨基酸位置2965至3534)进行等位基因特异性寡核苷酸杂交,发现了7种变异。在竞争性结合试验中,来自具有Arg 3500 Gln或Arg 3531 Cys的杂合子的LDL与LDL受体的结合存在缺陷。Arg 3500 Gln替代在高胆固醇血症患者中在统计学上更为普遍(P = 0.0003)。34名apoB 3500 Gln携带者的总胆固醇和低密度脂蛋白胆固醇显著高于对照组(P<0.0004)。编码Arg 3531 Cys替代的等位基因在CAD组中(0.8%)比对照组更普遍(P = 0.05)。Ser 3252 Gly变异在高胆固醇血症组中在统计学上更为普遍(P = 0.03),但带有这种突变的LDL具有正常的LDL受体结合活性。鉴定出的其他四种变异(Leu 3350 Leu、Gln 3405 Glu、Val 3396 Met和Ser 3455 Arg)与LDL受体结合缺陷、高胆固醇血症或CAD无关,apoB突变也与家庭成员血脂水平升高无关。令人惊讶的是,受体结合域中只有两种apoB突变(Arg 3500 Gln和Arg 3531 Cys)与LDL结合缺陷、高胆固醇血症或CAD相关,这与家族性高胆固醇血症形成鲜明对比,在家族性高胆固醇血症中,已经描述了近150种破坏LDL受体功能的突变。这项研究强烈表明,apoB的有限数量突变显著影响LDL与其受体的结合。